H.C. Wainwright reiterates Oruka Therapeutics stock rating at buy By Investing.com

Oruka Therapeutics reported positive EVERLAST-A Phase 2a data for ORKA-001, with 63.5% of 63 patients achieving PASI 100 at Week 16 and strong secondary endpoints (PASI 90 at 83%, IGA 0/1 at 84%). H.C. Wainwright reiterated Buy with a $120 target, while Clear Street and Barclays raised targets to $131 and $160, respectively, on confidence in the psoriasis program and annual-dosing profile. The company also priced an upsized 9.66 million-share offering at $72.50 for gross proceeds of about $700.4 million, underscoring both clinical momentum and active capital raising.

Analysis

ORKA is trading less like a single-asset biotech and more like a scarcity asset with a de-risked differentiated profile. If annual dosing holds, the company is effectively trying to collapse the normal psoriasis adoption curve by offering both efficacy and convenience, which matters because in this market the winner is not just the best biologic, but the one that can convert dermatology office workflow into a habit. That creates a second-order advantage versus incumbent IL-23s: fewer administrations should improve persistence, payer economics, and physician willingness to switch high-value chronic patients.

The bigger near-term dynamic is that the equity is now in a financing-to-validation transition. The large raise reduces existential risk, but it also raises the bar for visible execution because investors will be paying for multiple catalysts over the next 6-12 months rather than simply underwriting survival. In that setup, any signal that the annual-dose thesis compresses—PK durability, immunogenicity, injection logistics, or real-world tolerability—would hit the stock harder than a typical Phase 2 miss because the valuation is already discounting an unusually premium end-state.

Consensus seems to be missing how much of the current upside is already a duration trade on narrative continuation rather than a clean clinical arb. The stock can keep rerating if the data remain clean, but the move has likely outpaced the probability-adjusted clinical risk, so the better expression is not naked momentum chasing. The non-obvious risk is that the more ORKA is framed as 'best-in-disease,' the more it invites direct comparison to entrenched standards on durability, reimbursement, and switching friction—areas where commercial proof, not trial headlines, will decide whether the premium multiple sticks.

Key Decisions for Investors

• Stay long ORKA, but size as a catalyst-driven position rather than a core compounder; target a 1-3 month window into the next data/update cycle. Upside remains meaningful if annual dosing is confirmed, but risk of a sharp multiple reset is elevated after the run.
• Use call spreads instead of outright stock for ORKA into the next readout window: buy 3-6 month call spreads to express upside while capping premium paid. This is the cleaner way to capture rerating without taking full post-event drawdown risk.
• Consider a relative-value pair: long ORKA / short a basket of mature psoriasis incumbents such as ABBV on any rally, focusing on differentiation vs. market saturation. The trade works if ORKA continues to prove convenience-led share capture while incumbents remain valuation anchors.
• Do not add aggressively on strength after the recent financing; wait for either consolidation or a secondary pullback. The post-raise tape can stay bid, but incremental upside is better entered on volatility compression rather than headline momentum.
• Set a tight risk trigger around any durability or safety ambiguity in follow-up data over the next 3-6 months; if that appears, expect the stock to de-rate faster than peers because the current premium is built on a best-in-class assumption.